Healthcare Industry News:  Stem Cell Innovations 

Regenerative Medicine

 News Release - January 9, 2007

Stem Cell Innovations Announces Issuance of Fundamental Human Stem Cell Patent

HOUSTON--(HSMN NewsFeed)--Stem Cell Innovations, Inc. (OTCBB:SCLL ) announced today the issuance of a key patent covering human pluripotent stem cells in the United States. "The patent provides a broad blocking position for the pluripotent cells of interest to Stem Cell Innovations as it covers isolated human primordial germ cell derived pluripotent cells," said Stem Cell Innovations CEO Dr. James Kelly. "We believe that this is a fundamental patent in human stem cell biology and an important addition to our foundational IP." The patent was issued in the United States as U.S. Patent No. 7,153,684 and is licensed exclusively to Stem Cell Innovations.

Stem Cell Innovations is developing PluriCells(TM), a new human stem cell technology derived from primordial germ cells of fetal tissue. PluriCells are distinct from ES cells and are believed to be outside the competitive patents on human ES cells. Primordial germ cells are one of only two types of cells known to be able to produce any of the more than 200 cell types found in the human body. The primordial germ cells are the cells that eventually produce the sperm and the egg, passing the genome along to the next generation. Stem cell cultures generated from these cells are believed to have tremendous promise in advancing drug discovery and cell-based therapies for some of our most intractable health problems, such as neurodegenerative disease. Stem Cell Innovations is actively pursuing these applications, such as in the recently announced drug discovery program with the ALS Association.

About Stem Cell Innovations, Inc.

SCI is a cell biology company with facilities in Scotch Plains, NJ, Houston, TX and in Leiden, the Netherlands. Stem Cell Innovations proprietary, human pluripotent stem cells, known as PluriCells(TM), have the potential to aid in drug discovery, toxicology, and cell therapy. Stem Cell Innovations is in the process of making its patented pluripotent cell lines, which are eligible for federal funding in the U.S., widely available to universities and other not-for-profit institutions to rapidly advance stem cell research.

Stem Cell Innovations is positioned to become a leading provider of toxicology testing and discovery systems for the pharmaceutical, chemical, and nutraceutical industries around the world. The development of the proprietary PluriCell(TM) technology greatly expands the Company's currently marketed C3A human liver cell-based toxicology offerings.

Additional information is available at www.stemcellinnovations.com.

PluriCells is a Trademark of Stem Cell Innovations, Inc.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Forward-Looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects", "intends", "believes", "may", "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more or these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.


Source: Stem Cell Innovations

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps 2 - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps 2 - available on the Apple App Store for iPhone and iPad.